StemSight
StemSight is a Tampere, Finland-based biotech founded in 2021 that develops off-the-shelf iPS cell-derived cell therapies for corneal blindness, with lead candidate STE-101 targeting Limbal Stem Cell Deficiency and future expansion into corneal endothelial dystrophies.
- Company typePrivate
- Founded2021
- HeadquartersTampere, Finland
- Headcount11–50
- GTM typeB2B
- OfferingServices
What StemSight does
StemSight is a Tampere, Finland-based biotechnology company founded in 2021 that develops off-the-shelf cell therapies for corneal blindness, with a primary focus on Limbal Stem Cell Deficiency (LSCD). Its lead candidate STE-101 is an iPS cell-derived limbal stem cell therapy that replaces lost limbal stem cells to restore vision, and the product is positioned to benefit from Advanced Therapy Medicinal Product (ATMP) and Orphan Drug Designation frameworks. The platform combines induced pluripotent stem cell technology — developed by Nobel laureate Shinya Yamanaka and matured over 15+ years at Tampere University's Skottman Lab — with functional biomaterials (hyaluronic acid hydrogels) designed to simplify cell delivery and accelerate tissue regeneration. Differentiation methods produce corneal epithelial cells with validated ABCB5+ and ΔNp63α+ markers, and StemSight has additionally licensed CRISPR/Cas9 IP from ERS Genomics to enable selective gene knock-out in iPS cells. The company also participates in the €8M EU-funded KeratOPrinter consortium developing 3D bioprinted full-thickness corneas.
StemSight operates as a pre-clinical, venture-backed private company headquartered at Finn-Medi 5 in Tampere with a team of approximately 15 scientists and executives. Its go-to-market is built on enterprise/B2B biotech motions: future revenue is expected to flow through direct sales of cell therapy products to ophthalmology hospitals, specialty eye clinics, and healthcare systems, supplemented by licensing, co-development, and manufacturing partnerships with larger pharmaceutical and automation partners (e.g., Mytos for automated production). To date the company has financed operations through an approximately €500K pre-seed round (Voima Ventures, 2021), a €2.3M seed round (Voima Ventures-led with Business Finland non-dilutive funding, Stephen Industries, Biothom, 2025), and roughly €1.9M in cumulative non-dilutive grants (Business Finland Deep Tech Accelerator, Instrumentarium Science Foundation Silmu grant, WomenTechEU, and EU regional development funding).
The addressable indication is large — corneal blindness affects more than 12 million people globally and the company explicitly cites the donor-tissue shortage and the absence of treatment options for bilateral LSCD as the unmet need it is pursuing. Pricing of the eventual ATMP has not been disclosed and will be set upon regulatory approval through reimbursement negotiations with healthcare systems. The company has signaled a Series A financing round to fund clinical development and commercial preparation, with parallel platform expansion into corneal endothelial dystrophies and active outreach across European biotech investor events.
StemSight firmographics
Firmographics- Name
- StemSight
- Legal name
- StemSight
- Website
- https://stemsight.fi
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- StemSight is a Tampere, Finland-based biotech founded in 2021 that develops off-the-shelf iPS cell-derived cell therapies for corneal blindness, with lead candidate STE-101 targeting Limbal Stem Cell Deficiency and future expansion into corneal endothelial dystrophies.
- Ownership category
- akta.pro rank
StemSight industry classification
Industry- Product category
- Cell Therapy / Regenerative Ophthalmology
- akta.pro primary industry
- Ophthalmic Regeneration (cornea/retina) (HLAAAGAK)
- akta.pro secondary industries
- Stem Cell–Based Regenerative Therapies (HLAAAGAA), Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
Keywords
Where StemSight is headquartered
LocationHeadquarters
- HQ city
- Tampere
- HQ country
- Finland
- HQ region
- Europe
Offices1 record
Markets served
StemSight business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Cell Therapy Product Sales: StemSight develops and commercializes off-the-shelf cell therapy products (starting with STE-101 for LSCD) through direct sales to healthcare providers and hospital systems. Revenue will come from product sales to treating corneal blindness patients globally.
- Licensing and Partnerships: Future potential revenue through licensing of technology platform, co-development partnerships, and manufacturing partnerships with larger pharmaceutical companies for global distribution.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
StemSight product offering
Product offeringCore offering
StemSight develops off-the-shelf iPS cell-derived cell therapies combined with functional biomaterials to treat corneal blindness. Their lead product candidate STE-101 is an iPS-derived limbal stem cell therapy that replaces lost limbal stem cells to restore vision in patients with Limbal Stem Cell Deficiency (LSCD), without requiring genetic engineering or donor tissue.
Product overview
StemSight is a biotech company developing off-the-shelf cell therapies for corneal blindness. The company's core product is STE-101, an iPS cell-derived therapy for limbal stem cell deficiency (LSCD). StemSight combines induced pluripotent stem (iPS) cells with functional biomaterials to accelerate tissue regeneration and simplify cell delivery. Their technology platform is built on Nobel Prize-winning iPSC technology developed at Shinya Yamanaka's laboratory.
Differentiator
Problem solved
Functional benefit
Products and services
- STE-101 Off-the-shelf iPS cell-derived therapy for the treatment of limbal stem cell deficiency (LSCD), targeting partial or total unilateral or bilateral forms of the condition. The therapy replaces damaged limbal stem cells without requiring genetic engineering and is intended for ophthalmology hospitals and specialty eye clinics treating corneal blindness patients.
Quantifiable outcome
- Off-the-shelf cell therapy eliminating donor tissue dependency
- +1 more outcomes
Companies that use StemSight
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
StemSight technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
StemSight partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- MytoscoreMytos, a London-based biotechnology company automating cell manufacturing, announced a manufacturing collaboration with StemSight to integrate its iDEM automated platform for scaling production of StemSight's lead product STE-101. The collaboration aims to enable production of cell therapies from early clinical trials toward commercial-ready manufacturing, representing a validation of Mytos' technology and the industry shift toward automation in advanced cell therapies.
- KeratOPrinter Project ConsortiumcoreStemSight is part of the €8M EU-funded KeratOPrinter project aimed at revolutionizing corneal transplantation using advanced 3D bioprinting technology to create full-thickness, biocompatible corneas. The collaborative effort involves partners from five EU countries to address the global shortage of donor tissue and restore vision for millions.
- ERS GenomicscoreStemSight entered a licensing agreement with ERS Genomics for CRISPR/Cas9 foundational intellectual property. This Nobel-winning 'genetic scissors' technology allows selective knock-out of target genes in iPS cells, enabling trait modification that passes to resulting therapeutic cells.
- Tampere UniversitycoreFinnish Research Impact Foundation awarded StemSight and Tampere University's joint Tandem Industry Academia 2-year project. The technology originated from Professor Heli Skottman's Lab at Tampere University where academic research continues to develop new regenerative solutions.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
StemSight competitors and assessment
Company assessmentEmerging players
- ProKidney: US clinical-stage cell therapy company developing autologous cell therapies for kidney disease. Comparable as a clinical-stage, regenerative-medicine cell therapy developer, though focused on renal rather than ophthalmic indications.
- Sigilon Therapeutics: US clinical-stage biotech developing encapsulated cell therapies for chronic diseases. Comparable as an emerging allogeneic cell therapy company tackling complex delivery challenges, though its lead indications are non-ophthalmic.
Broad incumbents
- Mesoblast: Australian-listed late-stage cell therapy company commercializing allogeneic mesenchymal stem cell products (Remestemcel-L). Comparable as an established allogeneic cell therapy developer with regulatory experience in advanced therapies.
- Lineage Cell Therapeutics: US clinical-stage cell therapy company with programs in retinal/eye indications (e.g., OpRegen for dry AMD using RPE cells) and broader regenerative medicine. Overlaps as a cell therapy developer in ophthalmology, particularly for retinal diseases.
- Fate Therapeutics: US clinical-stage biotech developing iPSC-derived NK and T-cell immunotherapies using a proprietary iPSC platform. Comparable as a leading iPSC-derived allogeneic cell therapy company, though focused on oncology rather than ophthalmology.
- Pluristem Therapeutics: Israeli clinical-stage cell therapy company using placenta-derived mesenchymal-like adherent stromal cells (PLX cells). Comparable as an allogeneic, off-the-shelf cell therapy platform company, though targeting different indications.
Regional players
- Japan Tissue Engineering (J-TEC): Subsidiary of Teijin, J-TEC is the leading Japanese regenerative medicine company commercializing autologous corneal epithelial cell therapies (e.g., for LSCD) and other cell-based products. Comparable as a regional ophthalmic cell therapy player serving the Japanese market.
Direct peers
- Holostem Terapie Avanzate: Italian biotech that developed Holoclar, the first approved advanced therapy for LSCD (using autologous limbal stem cells). Holostem is the most direct competitor — both target LSCD with stem cell therapies, though Holostem uses autologous rather than allogeneic iPSC-derived cells.
- Cynata Therapeutics: Australia-listed clinical-stage biotech developing iPSC-derived cell therapies (Cymerus platform). Direct peer in iPSC-derived allogeneic cell therapy, and shares leadership lineage with StemSight (former Cynata CEO Ross Macdonald is now StemSight's CCO).
Others
- Catalent (Cell & Gene Therapy): Major CDMO with significant cell therapy manufacturing capabilities, often partnering with or supplying developers of allogeneic cell therapies including those in ophthalmology. Comparable as an enabling infrastructure partner in the cell therapy supply chain.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
StemSight social profiles
Digital presenceStemSight compliance and trust
Trust signalCompliance2 records
StemSight financial estimates
Financial estimateRevenue estimate
Valuation estimate
StemSight leadership team
Management profileNumber of profiles
Profiles18 records
StemSight funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
StemSight M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about StemSight
What does StemSight do?
StemSight develops off-the-shelf iPS cell-derived cell therapies combined with functional biomaterials to treat corneal blindness. Their lead product candidate STE-101 is an iPS-derived limbal stem cell therapy that replaces lost limbal stem cells to restore vision in patients with Limbal Stem Cell Deficiency (LSCD), without requiring genetic engineering or donor tissue.
Is StemSight a public or private company?
StemSight is a private company. It is classified as venture growth investor backed and is currently operating.
When was StemSight founded?
StemSight was founded in 2021. It employs 11 to 50 people.
Where is StemSight based?
StemSight is headquartered in Tampere, Finland, in the Europe region.
How does StemSight make money?
Two revenue lines are on record. Cell Therapy Product Sales are the primary driver. The others are licensing and Partnerships.
Who are StemSight's main competitors?
Emerging players on record are ProKidney and Sigilon Therapeutics. Broad incumbents are Mesoblast, Lineage Cell Therapeutics, Fate Therapeutics and Pluristem Therapeutics. Japan Tissue Engineering (J-TEC) is listed as a regional player. Direct peers are Holostem Terapie Avanzate and Cynata Therapeutics. Catalent (Cell & Gene Therapy) is listed as an others.
Does StemSight have an API?
No public API is recorded for StemSight.
What industry is StemSight in?
StemSight's product category is Cell Therapy / Regenerative Ophthalmology. Its primary akta.pro industry code is HLAAAGAK, Ophthalmic Regeneration (cornea/retina), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies.